Everett Harris & Co. CA Takes $211,000 Position in Agilent Technologies, Inc. (NYSE:A)

Everett Harris & Co. CA acquired a new stake in Agilent Technologies, Inc. (NYSE:A) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,520 shares of the medical research company’s stock, valued at approximately $211,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of A. WASHINGTON TRUST Co raised its position in shares of Agilent Technologies by 1,187.8% in the 4th quarter. WASHINGTON TRUST Co now owns 1,481 shares of the medical research company’s stock valued at $206,000 after purchasing an additional 1,366 shares in the last quarter. Courier Capital LLC acquired a new position in shares of Agilent Technologies in the 4th quarter valued at approximately $241,000. PFG Investments LLC acquired a new position in shares of Agilent Technologies in the 4th quarter valued at approximately $206,000. CVA Family Office LLC acquired a new position in shares of Agilent Technologies in the 4th quarter valued at approximately $68,000. Finally, Raymond James & Associates raised its position in shares of Agilent Technologies by 38.1% in the 4th quarter. Raymond James & Associates now owns 104,974 shares of the medical research company’s stock valued at $14,595,000 after purchasing an additional 28,965 shares in the last quarter.

Agilent Technologies Stock Performance

Shares of A stock traded down $1.91 during trading on Thursday, reaching $145.46. The company had a trading volume of 2,176,460 shares, compared to its average volume of 1,653,770. The firm’s 50 day simple moving average is $137.98 and its two-hundred day simple moving average is $126.28. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. Agilent Technologies, Inc. has a one year low of $96.80 and a one year high of $151.58. The company has a market capitalization of $42.63 billion, a PE ratio of 34.63, a PEG ratio of 4.37 and a beta of 1.11.

Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The firm had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company’s revenue was down 5.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.37 EPS. Sell-side analysts forecast that Agilent Technologies, Inc. will post 5.51 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd will be issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.65%. The ex-dividend date is Monday, April 1st. Agilent Technologies’s payout ratio is presently 22.38%.

Insider Transactions at Agilent Technologies

In related news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, SVP Philip Binns sold 2,827 shares of the business’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $147.54, for a total transaction of $417,095.58. Following the completion of the sale, the senior vice president now owns 9,997 shares in the company, valued at $1,474,957.38. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,610 shares of company stock valued at $9,220,333.

Analysts Set New Price Targets

Several research firms recently issued reports on A. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 19th. TheStreet raised Agilent Technologies from a “c+” rating to a “b-” rating in a research report on Friday, December 8th. Citigroup upped their price target on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. increased their target price on Agilent Technologies from $140.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. Finally, Evercore ISI dropped their target price on Agilent Technologies from $135.00 to $132.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $138.29.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.